Tolerability and PK [pharmacokinetics]/PD [pharmacodynamics] of multiple oral doses of CT53518 [tandutinib] in patients with acute myelogenous leukemia (AML)
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2008
At a glance
- Drugs Tandutinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 25 Sep 2005 New trial record.